TriLink BioTechnologies Announces Supply Agreement with Osmetech Molecular Diagnostics
News May 19, 2009
TriLink BioTechnologies, Inc. has announced that it has signed a service agreement with Osmetech Molecular Diagnostics to supply reagents for Osmetech's recently launched eSensor® Cystic Fibrosis Carrier Detection (CFCD) System and the eSensor® XT-8 System for Warfarin sensitivity.
As part of the agreement, TriLink is providing Osmetech with custom oligonucleotides, which are required reagents for the eSensor® detection systems.
"TriLink provides high quality reagents which have contributed to the excellent performance of our eSensor® products in the marketplace to date," said Osmetech Molecular Diagnostics COO, Pankaj Singhal.
"TriLink is proud to work with Osmetech in the advancement of this important science and rapidly developing commercial opportunity," said TriLink CEO, Dr. Richard Hogrefe.
About 422 million people around the world, including more than 30 million Americans, have diabetes. Obesity is the most significant risk factor for type 2 diabetes. yet about 30 percent of obese people do not develop type 2 diabetes or other metabolic conditions. New research aims to understand on a cellular level, how this separation occurs.READ MORE
Measuring hand grip can help identify youths who could benefit from lifestyle changes, says new research. While other studies have shown that muscle weakness as measured by grip strength is a predictor of unhealthy outcomes - including cardiovascular and metabolic diseases - this is the first to do so for adolescent health over time.READ MORE